Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

Takeda Pharmaceutical announced today it will buy Nimbus Therapeutics' experimental psoriasis drug, NDI-034858, for up to $6 billion. (Reuters)

Employing the same technology as its messenger RNA vaccines for COVID-19, Moderna, partnered with Merck, announced positive clinical trial results of a new skin cancer treatment. (Boston Globe)

In a clinical study, Dr. Kausik Si, working at Missouri-based Stower’s Institute, has genetically altered memory in animals, which may support future Alzheimer’s treatments. (KY3)

‍

‍
‍

Our Culture

“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.

Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”

   –Stephen, Lead Engineer

‍‍
‍

About Judi

Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

‍

‍

‍

‍